|
Select publications
ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(6453):60-2. Abstract
Diel IJ. Antitumour effects of bisphosphonates: First evidence and possible mechanisms. Drugs 2000;59(3):391-9. Abstract
Diel IJ et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63. Abstract
Howell on behalf of the ATAC Trialists’ Group. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. San Antonio Breast Cancer Symposium, 2004;Abstract 1.
Leighl NB et al. Phase II study of perifosine in metastatic or advanced breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1077.
Patel V et al. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002;62(5):1401-9. Abstract
Pegram MD et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). San Antonio Breast Cancer Symposium, 2004;Abstract 3039.
Pegram MD et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16(8):2659-71. Abstract
Powles T et al. Oral clodronate (BONEFOS) reduces skeletal complications and mortality in breast cancer patients with bone metastases: Retrospective analysis of patients from a randomized, placebocontrolled trial. San Antonio Breast Cancer Symposium, 2004;Abstract 3056.
Powles T et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20(15):3219-24. Abstract
Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: A clinical perspective. Cancer Treat Rev 2004;30(8):695-706. Abstract
Saarto T et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19(1):10-7. Abstract
Saarto T et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Proc ASCO 2004;Abstract 527.
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
|
